Regulatory MSD secures EC clearance for Keytruda combination therapy for ovarian cancer Pharmaceutical TechnologyMSD has received the EC approval for Keytruda along with paclitaxel, with or without bevacizumab, as a treatment for PD-L1-positive ovarian cancer.RegulatoryOncologyRead full story pharminent April 6, 2026 (Last updated: April 6, 2026) Pharmaceutical Technology MSD has received the EC approval for Keytruda along with paclitaxel, with or without bevacizumab, as a treatment for PD-L1-positive ovarian cancer. RegulatoryOncologyRead full story Post navigation Previous: Trump revives pharma tariffs with 100% charges, but leaves loopholesNext: Aspect Biosystems receives funding for cellular medicine project Related Stories Regulatory Scholar Rock’s muscle-targeting SMA therapy Isemblyd lands FDA approval pharminent September 14, 2026 Regulatory Psychedelic therapies ride wave of public favor into FDA hearing pharminent September 14, 2026 Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026